Cutera announced the international limited commercial release of AviClear, a 1726nm laser which targets and suppresses the production of sebum to treat acne at its source.
The company announced the limited release at the International Master Course on Aging Science (IMCAS) conference in Paris, France.
AviClear is now commercially available, on a limited basis, in the U.K., Europe, and Australia. Select practices will begin training on the technology in the coming weeks. Cutera also plans a steady rollout of AviClear across the U.K. and EU in 2024.
“It was moving to witness the excitement surrounding AviClear at IMCAS. The amount of physician and patient interest we have received since its initial inception has been tremendous,” says Brent Hauser, International President of Cutera, Inc., in a news release. “We are thrilled to be able to meet the broad demand for this type of treatment by steadily increasing availability and access globally.”
